Hikma Pharmaceuticals PLC closed 14.07% short of its 52-week high of £23.60, which the company reached on February 13th.

The expansion will grow domestic capacity across four sites and support the production of more than 12 billion doses of ...

So let's assess the underlying fundamentals over the last 3 years and see if they've moved in lock-step with shareholder returns. This technology could replace computers: discover the 20 stocks are ...

Hikma Pharmaceuticals PLC. Susan Ringdal. EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050. Steven Weiss. US Communications +1 732 788 8279.

On May 22, 2025, the FDA approved Bio-Thera Solutions and Hikma Pharmaceuticals’ ustekinumab biosimilar, STARJEMZA® (ustekinumab-hmny) injection, referencing Janssen’s STELARA® (ustekinumab ...

Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2024 Results Conference Call February 26, 2025 4:00 AM ET. ... You put on top of it some of the products that are coming in, ...

Hikma Pharmaceuticals PLC HIK shares rallied 1.73% to £21.12 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.69% to ...